Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone

American Journal of Physiology - Renal Physiology

Volumn 289, Issue 2 58-2, 2005, Pages

  Khan, Osman ^a   Riazi, Shahla ^a   Hu, Xinqun ^a   Song, Jian ^a   Wade, James B ^b   Ecelbarger, Carolyn A ^a,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Insulin resistance; TSC; Type II diabetes

Indexed keywords

ALDOSTERONE; CHLORIDE ION; CREATININE; GLUCOSE; HYDROCHLOROTHIAZIDE; INSULIN; POTASSIUM ION; RENIN; ROSIGLITAZONE; SODIUM ION; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CELLULAR DISTRIBUTION; CHLORIDE TRANSPORT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; IMMUNOBLOTTING; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ION TRANSPORT; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RAT STRAIN; SODIUM EXCRETION; SODIUM TRANSPORT; TREATMENT OUTCOME;

EID: 22344453139     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00335.2004     Document Type: Article

References (37)

1. Alonso-Galicia M, Brands MW, Zappe DH, and Hall JE. Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 28: 1047-1054, 1996.
2. 1 receptor function in obese Zucker rat. Clin Exp Hypertens 25: 35-47, 2003.
3. Bickel CA, Knepper MA, Verbalis JG, and Ecelbarger CA. Dysregulation of renal salt and water transport proteins in diabetic Zucker rats. Kidney Int 61: 2099-2110, 2002.
4. Bickel CA, Verbalis JG, Knepper MA, and Ecelbarger CA. Increased renal Na-K-ATPase, NCC, and β-ENaC abundance in obese Zucker rats. Am J Physiol Renal Physiol 281: F639-F648, 2001.
5. Bindels RJ, Hartog A, Timmermans JA, and van Os CH. Immunocytochemical localization of calbindin-D28k, calbindin-D9k and parvalbumin in rat kidney. Contrib Nephrol 91: 7-13, 1991.
6. Calnek DS, Mazzella L, Roser S, Roman J, and Hart CM. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 23: 52-57, 2003.
7. Coleman RA, Wu DC, Liu J, and Wade JB. Expression of aquaporins in the renal connecting tubule. Am J Physiol Renal Physiol 279: F874-F883, 2000.
8. Ecelbarger CA, Terris J, Frindt G, Echevarria M, Marples D, Nielsen S, and Knepper MA. Aquaporin-3 water channel localization and regulation in rat kidney. Am J Physiol Renal Fluid Electrolyte Physiol 269: F663-F672, 1995.
9. Frindt G, McNair T, Dahlmann A, Jacobs-Palmer E, and Palmer LG. Epithelial Na channels and short-term renal response to salt deprivation. Am J Physiol Renal Physiol 283: F717-F726, 2002.
10. Harker CT, O'Donnell MP, Kasiske BL, Keane WF, and Katz SA. The renin-angiotensin system in the type II diabetic obese Zucker rat. J Am Soc Nephrol 4: 1354-1361, 1993.
11. Hirsch IB, Kelly J, and Cooper S. Pulmonary edema associated with troglitazone therapy. Arch Intern Med 159: 1811, 1999.
12. Houseknecht KL, Cole BM, and Steele PJ. Peroxisome proliferator-activated receptor γ (PPARγ) and its ligands: a review. Domest Anim Endocrinol 22: 1-23, 2002.
13. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci 73: 2395-2411, 2003.
14. Ivarsen P, Frokiaer J, Aagaard NK, Hansen EF, Bendtsen F, Nielsen S, and Vilstrup H. Increased urinary excretion of aquaporin 2 in patients with liver cirrhosis. Gut 52: 1194-1199, 2003.
15. Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, and Knepper MA. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci USA 95: 14552-14557, 1998.
16. Komers R and Vrana A. Thiazolidinediones-tools for the research of metabolic syndrome X. Physiol Res 47: 215-225, 1998.
17. Martens FM, Visseren FL, Lemay J, de Koning EJ, and Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 62: 1463-1480, 2002.
18. Masilamani S, Kim GH, Mitchell C, Wade JB, and Knepper MA. Aldosterone-mediated regulation of ENaC α, β, and γ subunit proteins in rat kidney. J Clin Invest 104: R19-R23, 1999.
19. Masilamani SM, Wang X, Nielsen J, Ageloff SA, Brooks HL, and Knepper MA. Increased abundance of the thiazide-sensitive Na-Cl Co-transporter (NCC) in response to dietary NaCl restriction occurs in the absence of changes in NCC mRNA (Abstract). J Am Soc Nephrol 12: 36A, 2001.
20. + transporter proteins in urine. J Am Soc Nephrol 11: 2128-2132, 2000.
21. Nolan JJ, Jones NP, Patwardhan R, and Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17: 287-294, 2000.
22. Obermuller N, Bernstein P, Velazquez H, Reilly R, Moser D, Ellison DH, and Bachmann S. Expression of the thiazide-sensitive Na-Cl Co-transporter in rat and human kidney. Am J Physiol Renal Fluid Electrolyte Physiol 269: F900-F910, 1995.
23. Parving HH, Osterby R, Anderson PW, and Hsueh WA. Diabetic nephropathy. In: The Kidney (5th ed.), edited by Brenner BM. Philadelphia, PA: WB Saunders, 1996, p. 1864-1892.
24. Sato K, Sugawara A, Kudo M, Uruno A, Ito S, and Takeuchi K. Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertens Res 27: 417-425, 2004.
25. Song J, Hu X, Khan O, Tian Y, Verbalis JG, and Ecelbarger CA. Increased blood pressure, aldosterone activity, and regional differences in renal ENaC protein during vasopressin escape. Am J Physiol Renal Physiol 287: F1076-F1083, 2004.
26. Song J, Hu X, Shi M, Knepper MA, and Ecelbarger CA. Effects of dietary fat, NaCl, and fructose on renal sodium and water transporter abundances and systemic blood pressure. Am J Physiol Renal Physiol 287: F1204-F1212, 2004.
27. Song J, Knepper MA, Hu X, Verbalis JG, and Ecelbarger CA. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Phamacol Exp Ther 308: 426-433, 2004.
28. Sowers JR and Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 88: 63-82, 2004.
29. Thomas ML and Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 35: 123-124, 2001.
30. Umrani DN, Banday AA, Hussein T, and Lokhandwala MF. Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats. Hypertension 40: 880-885, 2002.
31. Velazquez H, Bartiss A, Bernstein P, and Ellison DH. Adrenal steroids stimulate thiazide-sensitive NaCl transport by rat renal distal tubules. Am J Physiol Renal Fluid Electrolyte Physiol 270: F211-F219, 1996.
32. Walker AB, Chattington PD, Buckingham RE, and Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48: 1448-1453, 1999.
33. Wang XY, Masilamani S, Nielsen J, K won TH, Brooks HL, Nielsen S, and Knepper MA. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest 108: 215-222, 2001.
34. Wilcox CS, Deng X, and Welch WJ. NO generation and action during changes in salt intake: roles of nNOS and macula densa. Am J Physiol Regul Integr Comp Physiol 274: R1588-R1593, 1998.
35. Williamson DF, Vinicor F, and Bowman BA. Primary prevention of type 2 diabetes mellitus by lifestyle intervention: implications for health policy. Ann Intern Med 140: 951-957, 2004.
36. Willson TM, Brown PJ, Sternbach DD, and Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 43: 527-550, 2000.
37. Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC III, Schnermann JB, and Briggs JP. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol Renal Physiol 277: F966-F973, 1999.